SCM
SUPN icon

Soleus Capital Management’s Supernus Pharmaceuticals SUPN Stock Holding History

Soleus Capital Management’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$24.2M Buy
+520,000
New +$25M 0.83% 34
2022
Q3 		– Sell
-258,100
Closed -$7.46M – 90
2022
Q2 		$7.46M Buy
258,100
+7,100
+3% +$203K 1.16% 32
2022
Q1 		$8.11M Buy
+251,000
New +$7.7M 1.05% 30

Other funds holding SUPN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return

Soleus Capital Management's SUPN Position: Q2 2026 in Review

Soleus Capital Management opened a new position in Supernus Pharmaceuticals (SUPN) in Q2 2026: 520,000 shares worth $24.2M. The stake represents 0.83% of the portfolio and ranks #34 among its holdings. This is a return to the name: Soleus Capital Management previously reported a position in SUPN as recently as Q2 2022.

Soleus Capital Management first reported a position in SUPN in Q1 2022 and has held it in 3 quarters since. 335 funds tracked by Wall St. Rank hold SUPN as of Q2 2026.

  • Soleus Capital Management held 520,000 shares of Supernus Pharmaceuticals worth $24.2M as of Q2 2026.
  • Supernus Pharmaceuticals was a new Soleus Capital Management position in Q2 2026.
  • Supernus Pharmaceuticals made up 0.83% of Soleus Capital Management's portfolio in Q2 2026, its #34 holding.
  • Soleus Capital Management first reported a position in Supernus Pharmaceuticals in Q1 2022 and has held it in 3 quarters since.
  • 335 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q2 2026.

Based on Soleus Capital Management's 13F filing for Q2 2026, filed 11 Aug 2026.